Arrivent
Newtown Square, US · Founded 2021 · 86 employees on LinkedIn · 9 known investors
Find your way into Arrivent
273 people in our graph share verified history with the Arrivent team — schools, employers, funds. One of them is your warm intro.
Detlev Biniszkiewiczunlockedknows Zhengbin (Bing) Yao · together at AstraZeneca (overlapped)
knows the team · via AstraZeneca
×6knows the team · via Amgen
×4knows the team · via University of Iowa
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers. Its pipeline centers on its lead candidate firmonertinib (formerly furmonertinib) and novel oncology therapeutics such as next-generation antibody drug conjugates.
Founders & leadership
Arrivent was founded in 2021 by Zhengbin (Bing) Yao.
Z(
Zhengbin (Bing) YaoinFounder · CEO and Chairman of Board of DirectorsZhengbin Yao is an Executive Officer and Director at ArriVent BioPharma, a clinical-stage biopharmaceutical company developing oncology therapeutics including antibody drug conjugates and its lead candidate firmonertinib. He brings expertise in biotechnology research and drug development across antibodies, proteins, and small molecules.
BR
Brent RiceinChief Commercial Officer
Board
JZ
Jason ZhangBoard director
CX
Cong XuBoard director
SL
Stuart LutzkerBoard director
Investors · 9
Catalio Capital Management, LPNew York
Foresite CapitalWest Hollywood
.png)
General CatalystSan Francisco · $30M
HongShan Capital GroupHong Kong · $100K – $50M
LAVHong Kong · $5M – $15M
Lilly Asia VenturesHong Kongvia Hongbo Lu · inferred
OrbiMedNew York · $1M – $75M
Sofinnova VenturesMenlo Park · $100K – $15M
NVIDIAreportedSanta Clara
Reported raises · per SEC filings
Form D private placements$260M disclosed across 2 rounds · 2021–2022
▶$110MraisedDec 2022 · 17 investors · BiotechnologyRule 506(b)
▶$110MraisedDec 2022 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stuart LutzkerDirector
- James HealyDirector
- Carl GordonDirector
- Jason ZhangDirector
- Zhengbin (Bing) YaoExecutive Officer, Director
- Bahija JallalDirector
- Cong XuDirector
- Offering amount
- $145M
- Amount sold
- $110M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$150MraisedFeb 2022 · 10 investors · BiotechnologyRule 506(b)
▶$150MraisedFeb 2022 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason ZhangDirector
- Cong XuDirector
- Zhengbin (Bing) YaoExecutive Officer, Director
- Stuart LutzkerDirector
- Offering amount
- $150M
- Amount sold
- $150M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
ArriVent BioPharma Reports Second Quarter 2026 Financial Results - BioSpacebiospace.com · Aug 2026
ArriVent BioPharma posts $93M H1 2026 net loss | AVBP Quarterly Report (10-Q)stocktitan.net · Aug 2026
Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWiregeekwire.com · Jul 2026Frequently asked questions
- What does Arrivent do?
- ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers. Its pipeline centers on its lead candidate firmonertinib (formerly furmonertinib) and novel oncology therapeutics such as next-generation antibody drug conjugates.
- Who founded Arrivent?
- Arrivent was founded by Zhengbin (Bing) Yao in 2021.
- Who are Arrivent's investors?
- Arrivent's investors include Catalio Capital Management, LP, Foresite Capital, General Catalyst, HongShan Capital Group, LAV, Lilly Asia Ventures, OrbiMed, Sofinnova Ventures and 1 more.
- How much funding has Arrivent raised?
- Arrivent has disclosed $260M raised across 2 rounds.
- Where is Arrivent headquartered?
- Arrivent is headquartered in Newtown Square, US.